{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:14:16Z","timestamp":1787004856358,"version":"build-2736575974"},"reference-count":60,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>Objective\u2003Our objective was to determine if treatment with pravastatin prevents preeclampsia in pregnant patients at risk of preeclampsia.<\/jats:p>\n                  <jats:p>Materials and Methods\u2003The study was performed in four major tertiary hospitals in Surabaya, Bandung, and Makassar between 2017 and 2021. Pregnant women at high risk of developing preeclampsia were recruited and randomized into an intervention group and control group. The control group received low-dose aspirin (80\u2009mg) and calcium (1\u2009g) daily, while the intervention group received additional pravastatin (20\u2009mg twice daily) starting from 14 to 20 weeks' gestation until delivery. The pregnancy was followed until delivery, and the clinical data were collected. The primary outcome was the occurrence of preeclampsia.<\/jats:p>\n                  <jats:p>Result\u2003A total of 173 people participated in this study, including 86 in the control group and 87 in the pravastatin group. The pravastatin group had a significantly lower rate of preterm preeclampsia (13.8 vs. 26.7%; p\u2009=\u20090.034; odds ratio [OR]\u2009=\u20090.034, 95% confidence interval [CI]\u2009=\u20090.202\u20130.905) and preterm birth (16.1 vs. 36%; p\u2009=\u20090.003; OR\u2009=\u20090.340, 95% CI\u2009=\u20090.165\u20130.7), mostly indicated preterm birth. Preeclampsia occurred later in the pravastatin group than in the control group (36.39\u2009+\u20092.32 vs. 34.89\u2009+\u20093.38 weeks, p\u2009=\u20090.048). Overall, the pravastatin group showed better perinatal outcomes. Neonates with low Apgar scores (&lt;7) at 1\u2009minute (5.7 vs. 25.6%, p\u2009=\u20090.000) and 5\u2009minutes (2.3 vs. 25.6%, p\u2009=\u20090.028) were significantly less common in the pravastatin group. Additionally, the rate of low birthweight babies (&lt;2,500\u2009g) was lower in the pravastatin group (27.6 vs. 40.7%; p\u2009=\u20090.069).<\/jats:p>\n                  <jats:p>Conclusion\u2003Pravastatin (20\u2009mg bid) significantly reduces the risk of preterm preeclampsia and preterm birth in women at a high risk of developing preeclampsia.<\/jats:p>\n                  <jats:p>Key Points<\/jats:p>","DOI":"10.1055\/a-1798-1925","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T20:11:12Z","timestamp":1647375072000},"page":"1203-1211","source":"Crossref","is-referenced-by-count":34,"title":["INOVASIA Study: A Multicenter Randomized Clinical Trial of Pravastatin to Prevent Preeclampsia in High-Risk Patients"],"prefix":"10.1055","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03648970","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-9282","authenticated-orcid":false,"given":"Muhammad Ilham Aldika","family":"Akbar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Airlangga, Department Obstetrics and Gynecology, Universitas Airlangga Hospital, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Alamsyah","family":"Azis","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Padjajaran, Department Obstetrics and Gynecology, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deviana Soraya","family":"Riu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Hasanudin, Department Obstetrics and Gynecology, Dr. Wahidin Sudirohusodo General Hospital, Makassar, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Wawengkang","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Hasanudin, Department Obstetrics and Gynecology, Dr. Wahidin Sudirohusodo General Hospital, Makassar, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernawati","family":"Ernawati","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Airlangga, Department Obstetrics and Gynecology, Universitas Airlangga Hospital, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Adrianes","family":"Bachnas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Sebelas Maret, Department Obstetrics and Gynecology, Dr. Moewardi General Hospital, Surakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri","family":"Sulistyowati","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Sebelas Maret, Department Obstetrics and Gynecology, Dr. Moewardi General Hospital, Surakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erry Gumilar","family":"Dachlan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Airlangga, Department Obstetrics and Gynecology, Universitas Airlangga Hospital, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanes Cornelius","family":"Mose","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Padjajaran, Department Obstetrics and Gynecology, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gus","family":"Dekker","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universitas Airlangga, Department Obstetrics and Gynecology, Universitas Airlangga Hospital, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia"},{"name":"Department Obstetrics and Gynecology, Lyell McEwin Hospital, The University of Adelaide, Adelaide, South Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"issue":"S 01","key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention","volume":"145","author":"L C Poon","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"issue":"76","key":"ref2","first-page":"168","article-title":"Gestational hypertension and preeclampsia","volume":"133","author":"ACOG","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","article-title":"Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice","volume":"72","author":"M A Brown","year":"2018","journal-title":"Hypertension"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S1171","DOI":"10.1016\/j.ajog.2020.08.040","article-title":"The role of statins in the prevention of preeclampsia","volume":"226","author":"D D Smith","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2215\/CJN.12081115","article-title":"Preeclampsia: updates in pathogenesis, definitions, and guidelines","volume":"11","author":"E Phipps","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"l2381","DOI":"10.1136\/bmj.l2381","article-title":"Pre-eclampsia: pathophysiology and clinical implications","volume":"366","author":"G J Burton","year":"2019","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(05)17987-2","article-title":"Pre-eclampsia","volume":"365","author":"B Sibai","year":"2005","journal-title":"Lancet"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","article-title":"Preeclampsia: pathophysiology, challenges, and perspectives","volume":"124","author":"S Rana","year":"2019","journal-title":"Circ Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(05)17987-2","article-title":"Pre-eclampsia","volume":"365","author":"B Sibai","year":"2005","journal-title":"Lancet"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"R J Levine","year":"2004","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.placenta.2008.11.021","article-title":"Placental stress and pre-eclampsia: a revised view","volume":"30","author":"C WG Redman","year":"2009","journal-title":"Placenta"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"S867","DOI":"10.1016\/j.ajog.2021.11.019","article-title":"Progress in the understanding of the pathophysiology of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to late-onset preeclampsia","volume":"226","author":"P Y Robillard","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/bph.12977","article-title":"Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?","volume":"172","author":"A Ahmed","year":"2015","journal-title":"Br J Pharmacol"},{"key":"ref14","first-page":"9.e1, S9\u2013S11","article-title":"Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity","volume":"213","author":"C WG Redman","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3346\/jkms.2007.22.5.873","article-title":"Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia","volume":"22","author":"S-Y Kim","year":"2007","journal-title":"J Korean Med Sci"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"e4453","DOI":"10.1371\/journal.pone.0004453","article-title":"Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia","volume":"4","author":"A Reddy","year":"2009","journal-title":"PLoS One"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jri.2013.12.120","article-title":"Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia","volume":"101-102","author":"W Ramma","year":"2014","journal-title":"J Reprod Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1042\/BST0371237","article-title":"Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?","volume":"37","author":"A Ahmed","year":"2009","journal-title":"Biochem Soc Trans"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","article-title":"Pleiotropic effects of statins. Basic research and clinical perspectives","volume":"74","author":"Q Zhou","year":"2010","journal-title":"Circ J"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.preghy.2020.11.014","article-title":"Effects of statins on preeclampsia: a systematic review","volume":"23","author":"A Vahedian-Azimi","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fphar.2017.00247","article-title":"The role of statins in prevention of preeclampsia: a promise for the future?","volume":"8","author":"V Katsi","year":"2017","journal-title":"Front Pharmacol"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14715\/cmb\/2018.64.10.1","article-title":"Role of statin as inducer of Hmox-1 system in treatment of preeclampsia","volume":"64","author":"R A Putra","year":"2018","journal-title":"Cell Mol Biol"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/HYPERTENSIONAHA.115.05445","article-title":"Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia","volume":"66","author":"F C Brownfoot","year":"2015","journal-title":"Hypertension"},{"issue":"25","key":"ref24","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1080\/14767058.2021.1879785","article-title":"Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study","volume":"35","author":"M IA Akbar","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/a-1673-5603","article-title":"INOVASIA Study: A Randomized Open Controlled Trial to Evaluate Pravastatin to Prevent Preeclampsia and Its Effects on sFlt1\/PlGF Levels","volume":"41","author":"M IA Akbar","year":"2024","journal-title":"Am J Perinatol"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/a-1673-5603","article-title":"INOVASIA Study: a randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effects on sFlt1\/PlGF Levels","volume":"41","author":"M IA Akbar","year":"2024","journal-title":"Am J Perinatol"},{"issue":"06","key":"ref27","first-page":"506","article-title":"The fetal safety of statins: a systematic review and meta-analysis","volume":"36","author":"J Zarek","year":"2014"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1701-2163(16)32656-1","article-title":"Risks of statin use during pregnancy: a systematic review","volume":"29","author":"A Kazmin","year":"2007","journal-title":"J Obstet Gynaecol Can"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/11632010-000000000-00000","article-title":"Statins and pregnancy: between supposed risks and theoretical benefits","volume":"72","author":"E Lecarpentier","year":"2012","journal-title":"Drugs"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2125.2007.02905.x","article-title":"Risk of congenital anomalies in pregnant users of statin drugs","volume":"64","author":"B Ofori","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1701-2163(16)32656-1","article-title":"Risks of statin use during pregnancy: a systematic review","volume":"29","author":"A Kazmin","year":"2007","journal-title":"J Obstet Gynaecol Can"},{"key":"ref32","volume-title":"The risks of statin use in pregnancy: a systematic review","author":"D G Karalis","year":"2016"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"M M Costantine","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/1471-0528.16013","article-title":"Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial","volume":"127","author":"A Ahmed","year":"2020","journal-title":"BJOG"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/1471-0528.12066","article-title":"Pregnancy outcome following maternal exposure to statins: a multicentre prospective study","volume":"120","author":"U Winterfeld","year":"2013","journal-title":"BJOG"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/AOG.0b013e31827d8ad5","article-title":"Pravastatin for the prevention of preeclampsia in high-risk pregnant women","volume":"121","author":"M M Costantine","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"666.e1","DOI":"10.1016\/j.ajog.2021.05.018","article-title":"A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia","volume":"225","author":"M M Costantine","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"02","key":"ref39","first-page":"1024","article-title":"Obesity and risk of preeclampsia","volume":"2","author":"H Itoh","year":"2014","journal-title":"Med J Obstet Gynecol"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1515\/jpm-2016-0418","article-title":"Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy","volume":"45","author":"R S Rocha","year":"2017","journal-title":"J Perinat Med"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/uog.5402","article-title":"Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia","volume":"32","author":"W Plasencia","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"07","key":"ref42","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/pd.4397","article-title":"First-trimester maternal factors and biomarker screening for preeclampsia","volume":"34","author":"L C Poon","year":"2014","journal-title":"Prenat Diagn"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GRF.0b013e3181fbb687","article-title":"Uterine artery Doppler and prediction of preeclampsia","volume":"53","author":"T R Lovgren","year":"2010","journal-title":"Clin Obstet Gynecol"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5005\/jp-journals-10009-1134","article-title":"Uterine artery Doppler in the prediction of preeclampsia and adverse pregnancy outcome","volume":"4","author":"A Antsaklis","year":"2010","journal-title":"Donald Sch J Ultrasound in Obs Gynecol"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-0038-1660777","article-title":"Uterine artery doppler in screening for preeclampsia and fetal growth restriction","volume":"40","author":"M A Pedroso","year":"2018","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"01","key":"ref46","first-page":"159","article-title":"ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002","volume":"99","author":"ACOG Committee on Practice Bulletins\u2013Obstetrics","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/ajcn\/64.4.650","article-title":"Anthropometric reference data for international use: recommendations from a World Health Organization Expert Committee","volume":"64","author":"M de Onis","year":"1996","journal-title":"Am J Clin Nutr"},{"key":"ref48","first-page":"1","article-title":"Pravastatin is useful for prevention of recurrent severe placenta-mediated complications\u2014a pilot study","author":"M J Kupferminc","year":"2021","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"12","key":"ref49","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"U Laufs","year":"1998","journal-title":"Circulation"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1172\/JCI1500","article-title":"Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells","volume":"101","author":"O Hern\u00e1ndez-Perera","year":"1998","journal-title":"J Clin Invest"},{"issue":"04","key":"ref51","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1073\/pnas.1011293108","article-title":"Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model","volume":"108","author":"K Kumasawa","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"05","key":"ref52","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1160\/TH12-05-0337","article-title":"Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation","volume":"108","author":"A S Antonopoulos","year":"2012","journal-title":"Thromb Haemost"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.preghy.2020.03.004","article-title":"Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction","volume":"20","author":"N de Alwis","year":"2020","journal-title":"Pregnancy Hypertens"},{"issue":"14","key":"ref54","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1055\/s-0040-1713651","article-title":"Evaluating the effect of pravastatin in early-onset fetal growth restriction: a nonrandomized and historically controlled pilot study","volume":"38","author":"M Mendoza","year":"2021","journal-title":"Am J Perinatol"},{"issue":"11","key":"ref55","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"A S Antonopoulos","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jri.2013.07.005","article-title":"Can statins prevent pregnancy complications?","volume":"101-102","author":"G Girardi","year":"2014","journal-title":"J Reprod Immunol"},{"issue":"25","key":"ref57","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1080\/14767058.2021.1879785","article-title":"Pravastatin suppresses inflammatory cytokines and endothelial activation in patients at risk of developing preeclampsia: INOVASIA study","volume":"35","author":"MIA Akbar","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"h1035","DOI":"10.1136\/bmj.h1035","article-title":"Statins and congenital malformations: cohort study","volume":"350","author":"B T Bateman","year":"2015","journal-title":"BMJ"},{"issue":"20","key":"ref59","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/ajmg.a.32493","article-title":"Maternal exposure to statins and risk for birth defects: a case-series approach","volume":"146A","author":"E E Petersen","year":"2008","journal-title":"Am J Med Genet A"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00003088-200039060-00002","article-title":"Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events","volume":"39","author":"T Hatanaka","year":"2000","journal-title":"Clin Pharmacokinet"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/OGX.0000000000000522","article-title":"Pravastatin for preventing and treating preeclampsia: a systematic review","volume":"73","author":"E Esteve-Valverde","year":"2018","journal-title":"Obstet Gynecol Surv"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1798-1925.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:44:20Z","timestamp":1730807060000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1798-1925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":60,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2024,6,18]]},"published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1798-1925","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,15]]},"published":{"date-parts":[[2022,3,15]]}}}